# SLC35G5

## Overview
SLC35G5 is a gene that encodes the protein solute carrier family 35 member G5, which is part of the solute carrier (SLC) family of proteins. These proteins are typically involved in the transport of various molecules across cellular membranes. The SLC35G5 protein is believed to play a role in cellular transport processes, although its specific substrates and mechanisms are not yet fully understood. Research has suggested potential implications of SLC35G5 in various clinical conditions, including chemotherapy resistance in high-grade serous ovarian carcinoma and medication-related osteonecrosis of the jaw, indicating its potential significance in medical genetics and pharmacogenomics (Marchocki2022Impact; Yang2021Genome‐wide). Further studies are needed to elucidate the precise functions and clinical relevance of this gene and its encoded protein.

## Clinical Significance
SLC35G5 has been implicated in various clinical contexts, although its precise role remains to be fully elucidated. In high-grade serous ovarian carcinoma (HGSC), SLC35G5 was identified as one of the genes mutated in tumor samples resistant to neoadjuvant chemotherapy (NACT). This suggests a potential role in predicting chemotherapy resistance, although the clinical significance of SLC35G5 in this context requires further validation (Marchocki2022Impact).

In the context of conotruncal heart defects, SLC35G5 showed suggestive evidence of association in a genome-wide association study (GWAS) involving individuals with and without 22q11.2 Deletion Syndrome. However, this association did not reach genome-wide significance, leaving its clinical relevance uncertain (Oluwafemi2021GenomeWide).

SLC35G5 has also been associated with medication-related osteonecrosis of the jaw (MRONJ) in patients treated with intravenous bisphosphonates. A significant locus on chromosome 8p23.1, which includes SLC35G5, was linked to an increased risk of MRONJ, highlighting its potential involvement in this condition (Yang2021Genome‐wide).

Overall, while SLC35G5 is associated with several conditions, its exact clinical significance and mechanisms of action remain areas for further research.


## References


[1. (Oluwafemi2021GenomeWide) Omobola O. Oluwafemi, Fadi I. Musfee, Laura E. Mitchell, Elizabeth Goldmuntz, Hongbo M. Xie, Hakon Hakonarson, Bernice E. Morrow, Tingwei Guo, Deanne M. Taylor, Donna M. McDonald-McGinn, Beverly S. Emanuel, and A. J. Agopian. Genome-wide association studies of conotruncal heart defects with normally related great vessels in the united states. Genes, 12(7):1030, July 2021. URL: http://dx.doi.org/10.3390/genes12071030, doi:10.3390/genes12071030. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/genes12071030)

[2. (Marchocki2022Impact) Zibi Marchocki, Alicia Tone, Carl Virtanen, Richard de Borja, Blaise Clarke, Theodore Brown, and Taymaa May. Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma. Journal of Ovarian Research, May 2022. URL: http://dx.doi.org/10.1186/s13048-022-00983-5, doi:10.1186/s13048-022-00983-5. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13048-022-00983-5)

[3. (Yang2021Genome‐wide) Guang Yang, Sonal Singh, Caitrin W. McDonough, Jatinder K. Lamba, Issam Hamadeh, L. Shannon Holliday, Danxin Wang, Joseph Katz, Peter A. Lakatos, Bernadett Balla, Janos P. Kosa, Gian Andrea Pelliccioni, Douglas K. Price, Sara L. Van Driest, William D. Figg, Taimour Langaee, Jan S. Moreb, and Yan Gong. Genome‐wide association study identified chromosome 8 locus associated with medication‐related osteonecrosis of the jaw. Clinical Pharmacology &amp; Therapeutics, 110(6):1558–1569, August 2021. URL: http://dx.doi.org/10.1002/cpt.2397, doi:10.1002/cpt.2397. This article has 8 citations.](https://doi.org/10.1002/cpt.2397)